BSS PLUS - balanced salt solution enriched with bicarbonate, dextrose, and glutathione Alcon Laboratories, Inc.

BSS PLUS® STERILE INTRAOCULAR IRRIGATING SOLUTION (balanced salt solution enriched with bicarbonate, dextrose, and glutathione)

DESCRIPTION: BSS PLUS[®] is a sterile intraocular irrigating solution for use during all intraocular surgical procedures, including those requiring a relatively long intraocular perfusion time (e.g., pars plana vitrectomy, phacoemulsification, extracapsular cataract extraction/lens aspiration, anterior segment reconstruction, etc.). The solution does not contain a preservative and should be prepared just prior to use in surgery.

Part I: Part I is a sterile 480 mL solution in a 500 mL single-dose bottle to which the Part II concentrate is added. Each mL of Part I contains: sodium chloride 7.44 mg, potassium chloride 0.395 mg, dibasic sodium phosphate 0.433 mg, sodium bicarbonate 2.19 mg, hydrochloric acid and/or sodium hydroxide (to adjust pH), in water for injection.

Part II: Part II is a sterile concentrate in a 20 mL single-dose vial for addition to Part I. Each mL of Part II contains: calcium chloride dihydrate 3.85 mg, magnesium chloride hexahydrate 5 mg, dextrose 23 mg, glutathione disulfide (oxidized glutathione) 4.6 mg, in water for injection.

After addition of BSS PLUS Part II to the Part I bottle, each mL of the reconstituted product contains: sodium chloride 7.14 mg, potassium chloride 0.38 mg, calcium chloride dihydrate 0.154 mg, magnesium chloride hexahydrate 0.2 mg, dibasic sodium phosphate 0.42 mg, sodium bicarbonate 2.1 mg, dextrose 0.92 mg, glutathione disulfide (oxidized glutathione) 0.184 mg, hydrochloric acid and/or sodium hydroxide (to adjust pH), in water for injection.

The reconstituted product has a pH of approximately 7.4. Osmolality is approximately 305 mOsm.

CLINICAL PHARMACOLOGY: None of the components of BSS PLUS are foreign to the eye, and BSS PLUS has no pharmacological action. Human perfused cornea studies have shown BSS PLUS to be an effective irrigation solution for providing corneal detumescence and maintaining corneal endothelial integrity during intraocular perfusion. An in vivo study in rabbits has shown that BSS PLUS is more suitable than normal saline or Balanced Salt Solution for intravitreal irrigation because BSS PLUS contains the appropriate bicarbonate, pH, and ionic composition necessary for the maintenance of normal retinal electrical activity. Human in vivo studies have demonstrated BSS PLUS to be safe and effective when used during surgical procedures such as pars plana vitrectomy, phacoemulsification, cataract extraction/lens aspiration, anterior segment reconstruction. No differences have been observed between adults and pediatric patients following use of this drug product.

INDICATIONS AND USAGE: BSS PLUS is indicated for use as an intraocular irrigating solution during intraocular surgical procedures involving perfusion of the eye.

CONTRAINDICATIONS: There are no specific contraindications to the use of BSS PLUS; however, contraindications for the surgical procedure during which BSS PLUS is to be used should be strictly adhered to.

WARNINGS: For IRRIGATION during ophthalmic surgery only. Not for injection or intravenous infusion. Do not use unless product is clear, seal is intact, vacuum is present and container is undamaged. Do not use if product is discolored or contains a precipitate.

PRECAUTIONS: DO NOT USE **BSS PLUS** UNTIL PART I IS FULLY RECONSTITUTED WITH PART II. Discard unused contents. BSS PLUS does not contain a preservative; therefore, do not use this container for more than one patient. DISCARD ANY UNUSED PORTION SIX HOURS AFTER PREPARATION. Studies suggest that intraocular irrigating solutions which are iso-osmotic with normal aqueous fluids should be used with caution in diabetic patients undergoing vitrectomy since intraoperative lens changes have been observed.

There have been reports of corneal clouding or edema following ocular surgery in which BSS PLUS was used as an irrigating solution. As in all surgical procedures appropriate measures should be taken to minimize trauma to the cornea and other ocular tissues.

Preparation: Reconstitute **BSS PLUS**® Intraocular Irrigating Solution just prior to use in surgery. Follow the same strict aseptic procedures in the reconstitution of **BSS PLUS** as is used for intravenous additives. Remove the blue flip-off seal from the **BSS PLUS** Part I (480 mL) bottle. Remove the blue flip-off seal from the **BSS PLUS** Part I (480 mL) bottle. Remove the blue flip-off seal from the **BSS PLUS** Part II (20 mL) vial. Clean and disinfect the rubber stoppers on both containers by using sterile alcohol wipes. Transfer the contents of the Part II vial to the Part I bottle using a **BSS PLUS** Vacuum Transfer Device (provided). An alternative method of solution transfer may be accomplished by using a 20 mL syringe to remove the Part II solution from the vial and transferring exactly 20 mL to the Part I container through the outer target area of the rubber stopper. An excess volume of Part II is provided in each vial. Gently agitate the contents to mix the solution. Place a sterile cap on the bottle. Remove the tear-off portion of the label. Record the time and date of reconstitution and the patient's name on the bottle label.

Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.

ADVERSE REACTIONS: Postoperative inflammatory reactions as well as incidents of corneal edema and corneal decompensation have been reported. Their relationship to the use of BSS PLUS has not been established.

OVERDOSAGE: The solution has no pharmacological action and thus no potential for overdosage. However, as with any intraocular surgical procedure, the duration of intraocular manipulation should be kept to a minimum.

DOSAGE AND ADMINISTRATION: The solution should be used according to the standard technique employed by the operating surgeon. Use an administration set with an air-inlet in the plastic spike since the bottle does not contain a separate airway tube. Follow the directions for the particular administration set to be used. Insert the spike aseptically into the bottle through the center target area of the rubber stopper. Allow the fluid to flow to remove air from the tubing before intraocular irrigation begins. If a second bottle is necessary to complete the surgical procedure, ensure that the vacuum is vented from the second bottle BEFORE attachment to the administration set.

HOW SUPPLIED: BSS PLUS is supplied in two packages for reconstitution prior to use: a 500 mL glass bottle containing 480 mL (Part I) and a 20 mL glass vial (Part II); both using grey butyl stoppers and aluminum seals with polypropylene flip-off caps. See the PRECAUTIONS section regarding reconstitution of the solution.

NDC 0065-0800-50.

- 1. Remove the blue flip-off seal from the BSS PLUS[®] Part I (480 mL) bottle. Remove the blue flip-off seal from the BSS PLUS Part II (20 mL) vial. Prepare the stoppers on both parts by using sterile alcohol wipes.
- 2. Peel open a BSS PLUS Vacuum Transfer Device package (supplied) and remove the sterile transfer spike.

NOTE: This device is vented permitting air to enter vial during solution transfer, thereby preventing the creation of a vacuum inside the vial. An air-inlet filter is provided to protect the system. Do not remove the air-inlet filter.

- 3. Remove protector from the white plastic piercing pin.
- 4. Firmly grasp device from behind the flange and insert the white plastic piercing pin into the upright rubber stopper of the BSS PLUS Part II (20 mL) vial.
- 5. Remove guard from filter needle. Firmly grasp vial in the palm of one hand and with thumb and index finger, hold plastic flange against top of vial.

- 6. Invert vial and immediately insert filter needle into the outer target of the rubber stopper of the BSS PLUS Part I (480 mL) bottle. (See illustration.)
- 7. Fluid will automatically transfer from the vial into the large vacuum bottle unless filter becomes occluded or loss of vacuum occurs. NOTE: An excess amount of BSS PLUS Part II is provided in each vial. A non-transferred solution residual of approximately 0.3 mL can be expected to remain in the vial.
- 8. Immediately remove needle from the BSS PLUS Part I container and discard it after solution transfer has been completed.
- 9. Place a sterile safety cap over the rubber stopper of Part I if the solution is not going to be used immediately. Mix the solution gently until uniform. Peel off the right-hand side of Part I bottle label (fully reconstituted BSS PLUS Solution). Record the patient's name and the date and time of reconstitution. BSS PLUS Solution is now ready for use.

CAUTION: Reconstituted BSS PLUS Solution must be used within six hours of mixing. Discard any solution which has aged beyond that time. Never use the same bottle of BSS PLUS Solution on more than one patient.

Alternative Transfer Method

If preferred, the contents of the BSS PLUS Part II component may be aspirated with an 18-gauge cannula attached to a 20 mL syringe and then transferred into the Part I bottle.

Alcon[®] a Novartis company

Distributed by: Alcon Laboratories, Inc. Fort Worth, Texas 76134 USA

Revised: November 2015

9012661-1115

Storage: Store Part I and Part II at 2° - 25°C (36° - 77° F). Discard prepared solution after six hours.

BSS PLUS[®] STERILE INTRAOCULAR IRRIGATING SOLUTION (balanced salt solution enriched with bicarbonate, dextrose, and glutathione)

RECONSTITUTION INSTRUCTIONS

HANGER DEVICE MUST BE ASSEMBLED PROPERLY PRIOR TO USE PART II VACUUM TRANSFER DEVICE PART I

DIRECTIONS: Use Aseptic Technique

- 1. Remove the blue flip-off seal from the BSS PLUS® Part I (480 mL) bottle. Remove the blue flip-off seal from the BSS PLUS Part II (20 mL) vial. Prepare the stoppers on both parts by using sterile alcohol wipes.
- 2. Peel open a BSS PLUS Vacuum Transfer Device package (supplied) and remove the sterile transfer spike.

NOTE: This device is vented permitting air to enter vial during solution transfer, thereby preventing the creation of a vacuum inside the vial. An air-inlet filter is provided to protect the system. Do not remove the air-inlet filter.

- 3. Remove protector from the white plastic piercing pin.
- 4. Firmly grasp device from behind the flange and insert the white plastic piercing pin into the upright

rubber stopper of the BSS PLUS Part II (20 mL) vial.

- 5. Remove guard from filter needle. Firmly grasp vial in the palm of one hand and with thumb and index finger, hold plastic flange against top of vial.
- 6. Invert vial and immediately insert filter needle into the outer target of the rubber stopper of the BSS PLUS Part I (480 mL) bottle. (See illustration.)
- 7. Fluid will automatically transfer from the vial into the large vacuum bottle unless filter becomes occluded or loss of vacuum occurs. NOTE: An excess amount of BSS PLUS Part II is provided in each vial. A non-transferred solution residual of approximately 0.3 mL can be expected to remain in the vial.
- 8. Immediately remove needle from the BSS PLUS Part I container and discard it after solution transfer has been completed.
- 9. Place a sterile safety cap over the rubber stopper of Part I if the solution is not going to be used immediately. Mix the solution gently until uniform. Peel off the right-hand side of Part I bottle label (fully reconstituted BSS PLUS Solution). Record the patient's name and the date and time of reconstitution. BSS PLUS Solution is now ready for use.

CAUTION: Reconstituted BSS PLUS Solution must be used within six hours of mixing. Discard any solution which has aged beyond that time. Never use the same bottle of BSS PLUS Solution on more than one patient.

Alternative Transfer Method

If preferred, the contents of the BSS PLUS Part II component may be aspirated with an 18-gauge cannula attached to a 20 mL syringe and then transferred into the Part I bottle.

Alcon[®] a Novartis company

Distributed by: Alcon Laboratories, Inc. Fort Worth, Texas 76134 USA

Revised: November 2015

W9013858-1016

PRINCIPAL DISPLAY PANEL

NDC 0065-0800-50

500 mL Single Patient Use

BSS PLUS[®] STERILE INTRAOCULAR IRRIGATING SOLUTION (balanced salt solution enriched with bicarbonate, dextrose, and glutathione)

After addition of BSS PLUS[®] – Part II (20 mL), each mL contains: sodium chloride 7.14 mg, potassium chloride 0.38 mg, calcium chloride dihydrate 0.154 mg, magnesium chloride hexahydrate 0.2 mg, dibasic sodium phosphate 0.42 mg, sodium bicarbonate 2.1 mg, dextrose 0.92 mg, glutathione disulfide (oxidized glutathione) 0.184 mg, hydrochloric acid and/or sodium hydroxide (to adjust pH), in water for injection.

pH Approx. 7.4 – Osmolality Approx. 305 mOsm/kg

Rx Only

WARNINGS: FOR IRRIGATION DURING OPHTHALMIC SURGERY ONLY. NOT FOR INJECTION OR INTRAVENOUS INFUSION. DO NOT USE UNLESS PRODUCT IS CLEAR, SEAL IS INTACT, VACUUM IS PRESENT AND CONTAINER IS UNDAMAGED. DO NOT USE IF PRODUCT IS DISCOLORED OR CONTAINS A PRECIPITATE.

PRECAUTIONS: DO NOT USE **BSS PLUS** UNTIL PART I IS FULLY RECONSTITUTED WITH PART II.

DISCARD UNUSED CONTENTS SIX HOURS AFTER PREPARATION. DO NOT USE THIS CONTAINER FOR MORE THAN ONE PATIENT.

Reconstitute just prior to use in surgery.

Alcon® a Novartis company

Alcon Laboratories, Inc.

Fort Worth, Texas 76134 USA ©2002-2003, 2015 Novartis

Patient Reconstituted at _____ AM/PM on_____

LOT:	
EXP.:	

SINGLE USE ONLY

NDC 0065-0800-50 480 mL

BSS PLUS[®] PART I **STERILE SOLUTION** (For Reconstitution by Addition of BSS PLUS[®] Concentrate Part II, 20 mL)*

Each mL contains: sodium chloride 7.44 mg, potassium chloride 0.395 mg, dibasic sodium phosphate 0.433 mg, sodium bicarbonate 2.19 mg, hydrochloric acid and/or sodium hydroxide (to adjust pH), in water for injection.

Rx Only

Storage: Store at 2° - 25°C (36° - 77°F).


WARNINGS: FOR IRRIGATION DURING OPHTHALMIC SURGERY ONLY AFTER RECONSTITUTION. DO NOT USE UNLESS PRODUCT IS CLEAR, SEAL IS INTACT, VACUUM IS PRESENT AND CONTAINER IS UNDAMAGED.

NOT FOR INJECTION OR INTRAVENOUS INFUSION

*Reconstitute just prior to use in surgery. Remove this part of label after reconstitution. Read

the Preparation and Administration sections of the package insert before reconstitution for important directions and precautions.

H14138-1115



NDC 0065-0800-50

20 mL

BSS PLUS[®] CONCENTRATE PART II (Sterile Solution for Reconstitution)

Alcon®

Alcon Laboratories Inc. Fort Worth, Texas 76134 USA

Each mL contains: calcium chloride dihydrate 3.85 mg, magnesium chloride hexahydrate 5 mg, dextrose 23 mg, glutathione disulfide (oxidized glutathione) 4.6 mg, in water for injection.

For Addition to **BSS PLUS[®]** — **Part I** (480 mL) only.

See **Preparation** section of package insert.

WARNINGS: Not for injection or intravenous infusion – for reconstitution of irrigation solution only. Do not use unless product is clear, seal is intact and container is undamaged. Do not use if product is discolored or contains a precipitate.

PRECAUTIONS: Discard unused contents. Do not use this container for more than one patient.

Storage: Store at 2°-25°C (36°-77°F).


Rx Only

©2002-2003, 2015 Novartis

H14142-1115

LOT:

EXP.:



BSS Plus[®] STERILE IRRIGATING SOLUTION (balanced salt solution enriched with bicarbonate, dextrose, and glutathione)

Carton Contents:

1 Vial **BSS PLUS**[®] Concentrate Part II Sterile Solution for Reconstitution with **BSS PLUS Part I** Only 1 **BSS PLUS** Vacuum Transfer Device

1 BSS PLUS Product Package Insert

WARNINGS: For IRRIGATION during ophthalmic surgery only. Not for injection or intravenous infusion. Do not use unless product is clear, seal is intact, vacuum is present and container is undamaged. Do not use if product is discolored or contains a precipitate.

Stare at 2°-35°C (36°-77°F). Discard prepared solution after six hours.

Alcon[®] a Novartis company

Alcon Laboratories Inc. Fort Worth, Texas 76134 USA © 2002, 2013, 2015 Novartis


PRECAUTIONS: DO NOT USE BSS PLUS® solution UNTIL PART I IS FULLY

RECONSTITUTED WITH PART II. Discard unused contents. **BSS PLUS** does not contain a preservative; therefore, do not use this container for more than one patient. DISCARD ANY UNUSED PORTION SIX HOURS AFTER PREPARATION. Studies suggest that intraocular irrigating solutions which are iso-osmotic with normal aqueous fluids should be used with caution in diabetic patients undergoing vitrectomy since intraoperative lens changes have been observed. There have been reports of corneal clouding or edema following ocular surgery in which **BSS PLUS** solution was used as an irrigating solutions. As in all surgical procedures, appropriate measures should be taken to minimize

trauma to the cornea and other ocular tissues.

LOT: EXP:

9012435-0116



BSS PLUS

balanced salt solution enriched with bicarbonate, dextrose, and glutathione kit

	nformati	on						
Product Ty	roduct Type HUMAN PRESCRIPTION DRUG			Item Code (Source)			NDC:0065-0800	
Packaging								
# Item	Code	Pac		Marke	eting Start Date	Ma	rketing End Date	
1 NDC:0065	NDC:0065-0800-50 1 in 1 PACKAGE; Type 0: Not a Comb			ation Product	06/28/1	982		
Quantity o	of Parts							
Part # Package Quantity					To	tal Product Qu	antit	v
Part 1 1BO	TTLE, GLA	_	-	480 mL				
Part 2 1 VIA	AL, SINGLE	-DOSE		20 mL				
Part 1 o PART 1								
balanced sa	alt solutior	n enriched with bi	icarbonate, dextro	se, and gluta	athione	solution		
Product I Route of Ad								
			HTHALMIC					
Active Ing	gredient/	Active Moiety	HTHALMIC					
Active Ing	gredient/					Basis of Stre	ngth	Strength
		Active Moiety/ Ingredie		/R4M0 NH37)		Basis of Stre Sodium Chloride	ngth	_
Sodium Chlo Potassium C	oride (UNII Chloride (U	(Active Moiety Ingredie : 451W47IQ8X) (Soc NII: 660YQ98110) (I	nt Name lium Cation - UNII:LY Potassium Cation - UI	NII:295053K15	2)	Sodium Chloride Potassium Chlorid	le	_
Sodium Chlo Potassium C Sodium Pho UNII:LYR4M0	oride (UNII Chloride (U sphate, Dil INH37)	' Active Moiety Ingredie : 451W47IQ8X) (Soc NII: 660YQ98110) (I basic (UNII: GR686)	nt Name lium Cation - UNII:LY Potassium Cation - UI LBA74) (Sodium Cati	NII:295053K15		Sodium Chloride Potassium Chlorid Sodium Phosphate Dibasic	le 2,	7.44 mg in 1 mL 0.395 mg in 1 mL 0.433 mg in 1 m
Sodium Chlo Potassium C Sodium Pho UNII:LYR4M0	oride (UNII Chloride (U sphate, Dil INH37)	' Active Moiety Ingredie : 451W47IQ8X) (Soc NII: 660YQ98110) (I basic (UNII: GR686)	nt Name lium Cation - UNII:LY Potassium Cation - UI	NII:295053K15		Sodium Chloride Potassium Chlorid Sodium Phosphate	le 2,	7.44 mg in 1 mL 0.395 mg in 1 mL
Sodium Chlo Potassium C Sodium Pho UNII:LYR4M0 Sodium Bica	oride (UNII Shloride (U sphate, Dil NH37) arbonate (1	(Active Moiety Ingredie : 451W47IQ8X) (Soc NII: 660 YQ98I10) (I basic (UNII: GR6861 UNII: 8MDF5V39QO	nt Name lium Cation - UNII:LY Potassium Cation - UI LBA74) (Sodium Cati	NII:295053K15		Sodium Chloride Potassium Chlorid Sodium Phosphate Dibasic	le 2,	7.44 mg in 1 mL 0.395 mg in 1 mL 0.433 mg in 1 m
Sodium Chlo Potassium C Sodium Pho UNII:LYR4M0 Sodium Bica	oride (UNII Shloride (U sphate, Dil NH37) arbonate (1	' Active Moiety Ingredie : 451W47IQ8X) (Soc NII: 660 YQ98110) (H basic (UNII: GR6861 UNII: 8MDF5V39QO	nt Name lium Cation - UNII:LY Potassium Cation - UI LBA74) (Sodium Cati	NII:295053K15		Sodium Chloride Potassium Chlorid Sodium Phosphate Dibasic	le 2,	7.44 mg in 1 mL 0.395 mg in 1 mL 0.433 mg in 1 m
Sodium Chlo Potassium C Sodium Pho UNII:LYR4M0 Sodium Bica Inactive In	oride (UNII Shloride (U sphate, Dil NH37) arbonate (I ngredien	' Active Moiety Ingredie : 451W47IQ8X) (Soc NII: 660 YQ98110) (H basic (UNII: GR6861 UNII: 8MDF5V39QO	nt Name lium Cation - UNII:LY Potassium Cation - UI LBA74) (Sodium Cati) (Sodium Cation - U	NII:295053K15		Sodium Chloride Potassium Chlorid Sodium Phosphate Dibasic	le 2,	7.44 mg in 1 mL 0.395 mg in 1 mL 0.433 mg in 1 m 2.19 mg in 1 mL
Sodium Chlo Potassium C Sodium Pho UNII:LYR4M0 Sodium Bica Inactive In Hydrochlori	oride (UNII Chloride (U sphate, Dil NH37) arbonate (1 ng re die n c Acid (UN	(Active Moiety Ingredie : 451W47IQ8X) (Soc NII: 660 YQ98110) (I basic (UNII: GR6861 UNII: 8MDF5V39QO UNII: 8MDF5V39QO	nt Name lium Cation - UNII:LY Potassium Cation - UI LBA74) (Sodium Cati) (Sodium Cation - U	NII:295053K15		Sodium Chloride Potassium Chlorid Sodium Phosphate Dibasic	le 2,	7.44 mg in 1 mL 0.395 mg in 1 mL 0.433 mg in 1 m 2.19 mg in 1 mL
Sodium Chlo Potassium C Sodium Pho UNII:LYR4M0 Sodium Bica Inactive In Hydrochlori Sodium Hyd	oride (UNII Shloride (U sphate, Dil NH37) arbonate (U ngredien c Acid (UN roxide (UN	(Active Moiety Ingredie : 451W47IQ8X) (Soc NII: 660 YQ98I10) (I basic (UNII: GR686I UNII: 8MDF5V39QO IUNII: 8MDF5V39QO III: QTT17582CB) III: 255X04QC32I)	nt Name lium Cation - UNII:LY Potassium Cation - UI LBA74) (Sodium Cati) (Sodium Cation - U	NII:295053K15		Sodium Chloride Potassium Chlorid Sodium Phosphate Dibasic	le 2,	7.44 mg in 1 mL 0.395 mg in 1 mL 0.433 mg in 1 m 2.19 mg in 1 mL
Sodium Chlo Potassium C Sodium Pho UNII:LYR4M0 Sodium Bica Inactive In Hydrochlori Sodium Hyd Water (UNII:	oride (UNII Shloride (U sphate, Dil NH37) arbonate (U ngredien c Acid (UN roxide (UN 059QF0KC	(Active Moiety Ingredie : 451W47IQ8X) (Soc NII: 660 YQ98I10) (I basic (UNII: GR686I UNII: 8MDF5V39QO IUNII: 8MDF5V39QO III: QTT17582CB) III: 255X04QC32I)	nt Name lium Cation - UNII:LY Potassium Cation - UI LBA74) (Sodium Cati) (Sodium Cation - U	NII:295053K15		Sodium Chloride Potassium Chlorid Sodium Phosphate Dibasic	le 2,	7.44 mg in 1 mL 0.395 mg in 1 mL 0.433 mg in 1 m 2.19 mg in 1 mL
Sodium Chlo Potassium C Sodium Pho UNII:LYR4M0 Sodium Bica Inactive In Hydrochlori Sodium Hyd Water (UNII: Packaging	oride (UNII Shloride (U sphate, Dil NH37) arbonate (U ngredien c Acid (UN roxide (UN 059QF0KC	<pre>/Active Moiety Ingredie : 451W47IQ8X) (Soc NII: 660 YQ98110) (F basic (UNII: GR6861 UNII: 8MDF5V39QO nts III: 8MDF5V39QO nts III: 2TT17582CB) III: 55X04QC32I) OOR)</pre>	nt Name lium Cation - UNII:LY Potassium Cation - UI LBA74) (Sodium Cati) (Sodium Cation - U	NII:295053K15	B7)	Sodium Chloride Potassium Chlorid Sodium Phosphate Dibasic Sodium Bicarbon	le 2, ate	7.44 mg in 1 mL 0.395 mg in 1 mL 0.433 mg in 1 m 2.19 mg in 1 mL
Sodium Chlo Potassium C Sodium Pho UNII:LYR4M0 Sodium Bica Inactive In Hydrochlori Sodium Hyd Water (UNII:	oride (UNII Shloride (U sphate, Dil NH37) arbonate (U ngredien c Acid (UN roxide (UN 059QF0KC	<pre>/Active Moiety Ingredie : 451W47IQ8X) (Soc NII: 660 YQ98110) (F basic (UNII: GR6861 UNII: 8MDF5V39QO nts III: 8MDF5V39QO nts III: 2TT17582CB) III: 55X04QC32I) OOR)</pre>	nt Name lium Cation - UNII:LY Potassium Cation - UI LBA74) (Sodium Cati) (Sodium Cation - U	NII:295053K15	B7)	Sodium Chloride Potassium Chlorid Sodium Phosphate Dibasic Sodium Bicarbon	le 2, ate	7.44 mg in 1 mL 0.395 mg in 1 mL 0.433 mg in 1 m 2.19 mg in 1 mL

Marketing	Information					
Marketing Cat	ategory Application Number or Monograph Citation Mark			ng Start Date	Marl	keting End Date
NDA	NDA018469 06/28/1982					
Part 2 of 2						
PART II						
calcium chloric	le, magnesium chlo	oride, dextrose, and glutathione cor	centrate			
Product Info	rmation					
Route of Admir		OPHTHALMIC				
Route of Adhin	listration	OFIITIALMIC				
Active Ingree	dient/Active Moi	etv				
0		redient Name		Basis of Stre	ngth	Strength
Ingredient Name Calcium Chloride (UNII: M410D6VV5M) (Calcium Cation - UNII:2M83C4R6ZB)					_	3.85 mg in 1 mL
Calcium Chlorid	M) (Calcium Cation - UNII:2M83C4R6ZB)		Calcium Chlorid	e	5.05 mg m i m	
			338)			_
Magnesium Chlo	oride (UNII: 02F3473F	190) (Magnesium Cation - UNII:T6V3LHY	338)	Magnesium Chlorid		5 mg in 1 mL
Magnesium Chlo Dextrose (UNII: Г	oride (UNII: 02F3473F Y9XDZ35W2) (Dextros		338)	Magnesium Chlo		_
Magnesium Chlo Dextrose (UNII: F Oxiglutatione (I	oride (UNII: 02F3473F Y9XDZ35W2) (Dextros JNII: ULW86O013H) (redients	190) (Magnesium Cation - UNII:T6V3LHY se - UNII:IY9XDZ35W2) Oxiglutatione - UNII:ULW860013H)	338)	Magnesium Chlo Dextrose	oride	5 mg in 1 mL 23 mg in 1 mL 4.6 mg in 1 mL
Magnesium Chlo Dextrose (UNII: F Oxiglutatione (I Inactive Ingr	oride (UNII: 02F3473F Y9XDZ35W2) (Dextros JNII: ULW86O013H) (redients In	19O) (Magnesium Cation - UNII:T6V3LHY se - UNII:IY9XDZ35W2)	338)	Magnesium Chlo Dextrose		5 mg in 1 mL 23 mg in 1 mL 4.6 mg in 1 mL
Magnesium Chlo Dextrose (UNII: F Oxiglutatione (I Inactive Ingr	oride (UNII: 02F3473F Y9XDZ35W2) (Dextros JNII: ULW86O013H) (redients In	190) (Magnesium Cation - UNII:T6V3LHY se - UNII:IY9XDZ35W2) Oxiglutatione - UNII:ULW860013H)	338)	Magnesium Chlo Dextrose	oride	5 mg in 1 mL 23 mg in 1 mL 4.6 mg in 1 mL
Magnesium Chlo Dextrose (UNII: F Oxiglutatione (U Inactive Ingr Water (UNII: 059 Packaging	oride (UNII: 02F3473F Y9XDZ35W2) (Dextros JNII: ULW86O013H) (redients In	190) (Magnesium Cation - UNII:T6V3LHY se - UNII:IY9XDZ35W2) Oxiglutatione - UNII:ULW860013H)		Magnesium Chlo Dextrose Oxiglutatione	Stre:	5 mg in 1 mL 23 mg in 1 mL 4.6 mg in 1 mL
Magnesium Chlo Dextrose (UNII: F Oxiglutatione (I Inactive Ingr Water (UNII: 059 Packaging	oride (UNII: 02F3473F Y9XDZ35W2) (Dextros JNII: ULW86O013H) (redients II QF0KO0R)	190) (Magnesium Cation - UNII:T6V3LHY se - UNII:IY9XDZ35W2) Oxiglutatione - UNII:ULW860013H)		Magnesium Chlo Dextrose	Stre:	5 mg in 1 mL 23 mg in 1 mL 4.6 mg in 1 mL
Magnesium Chlo Dextrose (UNII: F Oxiglutatione (U Inactive Ingr Water (UNII: 059 Packaging H Item Code	Pride (UNII: 02F3473F Y9XDZ35W2) (Dextros JNII: ULW86O013H) (Pedients In QF0K00R) P	190) (Magnesium Cation - UNII:T6V3LHY se - UNII:IY9XDZ35W2) Oxiglutatione - UNII:ULW860013H) ngredient Name		Magnesium Chlo Dextrose Oxiglutatione	Stre:	5 mg in 1 mL 23 mg in 1 mL 4.6 mg in 1 mL ngth
Magnesium Chlo Dextrose (UNII: F Oxiglutatione (U Inactive Ingr Water (UNII: 059 Packaging H Item Code	P oride (UNII: 02F3473F Y9XDZ35W2) (Dextroson JNII: ULW86O013H) (redients In QF0KO0R) P 20 mL in 1 VIAL, SING	190) (Magnesium Cation - UNII:T6V3LHY se - UNII:IY9XDZ35W2) Oxiglutatione - UNII:ULW860013H) ngredient Name		Magnesium Chlo Dextrose Oxiglutatione	Stre:	5 mg in 1 mL 23 mg in 1 mL 4.6 mg in 1 mL ngth
Magnesium Chlo Dextrose (UNII: F Oxiglutatione (U Inactive Ingr Water (UNII: 059 Packaging H Item Code I 2 Barketing	e dients Information	19O) (Magnesium Cation - UNII:T6 V3LHY se - UNII:IY9 XDZ35W2) Oxiglutatione - UNII:ULW86O013H) ngredient Name ackage Description LE-DOSE; Type 0: Not a Combination	Mar	Magnesium Chlo Dextrose Oxiglutatione	Stre M	5 mg in 1 mL 23 mg in 1 mL 4.6 mg in 1 mL ngth
Magnesium Chlo Dextrose (UNII: F Oxiglutatione (T Inactive Ingr Water (UNII: 059 Packaging # Item Code 1 2 2 Marketing	Paride (UNII: 02F3473F Y9XDZ35W2) (Dextroson JNII: ULW86O013H) (Pedients In QF0KO0R) P ComL in 1 VIAL, SING Product Information egory Application	190) (Magnesium Cation - UNII:T6V3LHY se - UNII:IY9XDZ35W2) Oxiglutatione - UNII:ULW860013H) ngredient Name	Marketi	Magnesium Chlo Dextrose Oxiglutatione	Stre M	5 mg in 1 mL 23 mg in 1 mL 4.6 mg in 1 mL ngth
Magnesium Chlo Dextrose (UNII: F Oxiglutatione (T Inactive Ingr Water (UNII: 059 Packaging H Item Code 1 2 2	e dients Information	19O) (Magnesium Cation - UNII:T6 V3LHY se - UNII:IY9 XDZ35W2) Oxiglutatione - UNII:ULW86O013H) ngredient Name ackage Description LE-DOSE; Type 0: Not a Combination	Mar	Magnesium Chlo Dextrose Oxiglutatione	Stre M	5 mg in 1 mL 23 mg in 1 mL 4.6 mg in 1 mL ngth
Magnesium Chlo Dextrose (UNII: F Oxiglutatione (U Inactive Ingr Water (UNII: 059 Packaging # Item f Code 1 2 2 Marketing Cat NDA	e dients Information e gory Application NDA018469	19O) (Magnesium Cation - UNII:T6 V3LHY se - UNII:IY9 XDZ35W2) Oxiglutatione - UNII:ULW86O013H) ngredient Name ackage Description LE-DOSE; Type 0: Not a Combination	Marketi	Magnesium Chlo Dextrose Oxiglutatione	Stre M	5 mg in 1 mL 23 mg in 1 mL 4.6 mg in 1 mL ngth
Magnesium Chlo Dextrose (UNII: F Oxiglutatione (U Inactive Ingr Water (UNII: 059 Packaging # Item f Code 1 Code 2 Marketing Cat NDA	oride (UNII: 02F3473F Y9XDZ35W2) (Dextroson JNII: ULW86O013H) (redients In QF0KO0R) P 20 mL in 1 VIAL, SING Product Information egory Application NDA018469	19O) (Magnesium Cation - UNII:T6 V3LHY se - UNII:IY9 XDZ35W2) Oxiglutatione - UNII:ULW86O013H) agredient Name ackage Description LE-DOSE; Type 0: Not a Combination on Number or Monograph Citation	Marketi 06/28/198	Magnesium Chlo Dextrose Oxiglutatione	Stre	5 mg in 1 mL 23 mg in 1 mL 4.6 mg in 1 mL ng th farketing End Date
Magnesium Chlo Dextrose (UNII: F Oxiglutatione (U Inactive Ingr Water (UNII: 059 Packaging # Item f Code 1 2 2 Marketing Cat NDA	oride (UNII: 02F3473F Y9XDZ35W2) (Dextroson JNII: ULW86O013H) (redients In QF0KO0R) P 20 mL in 1 VIAL, SING Product Information egory Application NDA018469	19O) (Magnesium Cation - UNII:T6 V3LHY se - UNII:IY9 XDZ35W2) Oxiglutatione - UNII:ULW86O013H) ngredient Name ackage Description LE-DOSE; Type 0: Not a Combination	Marketi 06/28/198	Magnesium Chlo Dextrose Oxiglutatione	Stre	5 mg in 1 mL 23 mg in 1 mL 4.6 mg in 1 mL ngth

Labeler - Alcon Laboratories, Inc. (008018525)

Registrant - Alcon Laboratories, Inc. (008018525)

Establishment

Name	Address	ID/FEI	Business Operations
Alcon Research LLC		007672236	manufacture(0065-0800)

Revised: 11/2019

Alcon Laboratories, Inc.